Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

DOI

10.2991/978-94-6463-112-8_16How to use a DOI?

Keywords

Single-tablet regimen; tenofovir lamivudine efavirenz; HIV

Abstract

Tenofovir lamivudine efavirenz (TLE) as a single-tablet regimen is preferred to the long use of combination antiretroviral therapy. TLE is safer than another antiretroviral drug regimen for first-line of Human immunodeficiency virus (HIV) treatment. However, there is little information about the side effects of TLE during first-time therapy among people living with HIV in Jayapura. This study aimed to assess the TLE side effect and its efficacy among people living with HIV in Jayapura, Papua. This was a cross-sectional study involving 77 people living with HIV who took a single-tablet regimen of TLE for one to two years of antiretroviral therapy, comply the inclusion criteria, and provided consent to participate. Data collection was conducted through CD4 + tests, medical records, and interviews at Jayapura City Hospital. Descriptive statistics were used to determine the proportion of relevant variables. The results described that most groups of people living with HIV were adult group (93.5%), female (61.0%), Papuan (64.9%), had WHO clinical stage III-IV (67.5%), had CD4 + counts < 350 cell/μL in the early therapy (79.2%) and CD4 + counts ≥ 350 cell/μL at the time of the study (57.1%), and experienced TLE side effect (71.4%). The most symptoms of TLE side effects among people living with HIV were headache (61.8%), nausea (34.5%), and nightmare (29.1%). As many as 70.9% of people living with HIV experienced these symptoms for less than 2 weeks. TLE was still effective, indicated by an increase of CD4 + cell count average from 242.6 cell/mm³ at the early therapy to 436.6 cell/mm³ during this study, with good adherence to drug therapy (>95% adherence) by 53.2% of people living with HIV. The side effects of TLE can still be tolerated by most people living with HIV so the therapy can be continued without altering the regimen.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Setyo Adiningsih
AU  - Mirna Widiyanti
AU  - Muhammad F. Rokhmad
PY  - 2023
DA  - 2023/03/01
TI  - Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura
BT  - Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)
PB  - Atlantis Press
SP  - 158
EP  - 169
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-112-8_16
DO  - 10.2991/978-94-6463-112-8_16
ID  - Adiningsih2023
ER  -